Physiomics Share News (PYC)

Physiomics Information

Buy PYC Shares
Add PYC to Watchlist
Add PYC to Alert

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1.30

Bid: 1.20

Ask: 1.40

Change: -0.20 (-13.33%)

Spread: 0.20 (16.667%)

Open: 1.25

High: 1.30

Low: 1.05

Prev. Close: 1.50

Last checked at -

IN BRIEF: Physiomics wins first contract from Numab Therapeutics

Tue, 11th May 2021 17:50

Physiomics PLC - oncology consultant based in Oxford - Awarded its first contract by Zurich-based biopharmaceutical company Numab Therapeutics, which is focused on developing biotherapeutics for chronic inflammation and cancer.

"We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team," notes Chief Executive Officer Jim Millen.

Current stock price: 5.91 pence

Year-to-date change: down 20%

By Dayo Laniyan; dayolaniyan@alliancenews.com

More News

14 May 2021 10:23

AIM WINNERS & LOSERS: Velocity and Physiomics boosted by contract wins

14 May 2021 09:27

Physiomics secures follow-on contract from Merck KgaA

14 May 2021 08:27

Physiomics secures additional contract with Merck

(Sharecast News) - Drug development consultancy Physiomics has been awarded a further contract with a leading science and technology company Merck.

11 May 2021 10:46

Physiomics secures contract with Numab Therapeutics

(Sharecast News) - Consultancy firm Physiomics said on Tuesday that it has been awarded a first contract with new client Numab Therapeutics.

10 May 2021 10:21

Physiomics says full-year results to disappoint market forecasts

10 May 2021 10:19

AIM WINNERS & LOSERS: Corcel rises on "shovel ready" Tring Road stake

10 May 2021 08:40

Physiomics FY income likely to fall short of market expectations

(Sharecast News) - Technology-based solutions provider Physiomics said on Monday that total income for the financial year ending 30 June was likely to be below market expectations due to both Covid-19 related project delays and an increased focus on longer-term value-generating activities.

1 Mar 2021 11:29

AIM WINNERS & LOSERS: Tlou Energy rises on project funding hopes

1 Mar 2021 11:22

TRADING UPDATES: CentralNic revenue doubles; Augean swing to profit

15 Feb 2021 16:04

Physiomics and ValiRx enter new collaboration deal

(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.

15 Feb 2021 11:05

Latest Share Chat

Physiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

IN BRIEF: Physiomics wins first contract from Numab Therapeutics

AIM WINNERS & LOSERS: Velocity and Physiomics boosted by contract wins

Physiomics secures follow-on contract from Merck KgaA

Physiomics secures additional contract with Merck

Physiomics secures contract with Numab Therapeutics

Physiomics says full-year results to disappoint market forecasts

AIM WINNERS & LOSERS: Corcel rises on "shovel ready" Tring Road stake

Physiomics FY income likely to fall short of market expectations

AIM WINNERS & LOSERS: Tlou Energy rises on project funding hopes

TRADING UPDATES: CentralNic revenue doubles; Augean swing to profit

Physiomics and ValiRx enter new collaboration deal

IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics

UK TRADING UPDATE SUMMARY: Focusrite Revenue Grows On Strong Demand

Physiomics gets initial 2021 commitment from client Merck

UK TRADING UPDATE SUMMARY: Airtel Investor To Sell 60 Million Shares

Latest Share Chat

Physiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Physiomics wins first contract from Numab Therapeutics

Login to your account

Quickpicks are a member only feature

Login to your account